Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL
Clinical trial NCT06188676 · RECRUITING
Trial details
- NCT number
- NCT06188676
- Sponsor
- National Research Center for Hematology, Russia
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-01
- Primary completion
- 2029-04-01
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.